1092304-85-2 Usage
Uses
Used in Organic Synthesis:
8-Bromoquinolin-2-amine is used as a key intermediate in the synthesis of various organic compounds. Its reactivity, stemming from the bromine atom and amine group, allows for the creation of new molecules with potential applications in different industries.
Used in Pharmaceutical Research:
8-Bromoquinolin-2-amine is employed as a building block in the development of new pharmaceuticals. Its unique structure and reactivity enable the design and synthesis of novel drug candidates, potentially leading to the discovery of new treatments for various diseases and conditions.
Used in Chemical Reactions:
8-Bromoquinolin-2-amine is used as a reactant in various chemical reactions, such as substitution, addition, and condensation reactions. Its presence in these reactions can lead to the formation of new compounds with diverse properties and potential applications.
Used in Research and Development:
8-Bromoquinolin-2-amine is utilized in research and development settings to explore its properties, reactivity, and potential applications. This can include studying its interactions with other compounds, understanding its role in chemical reactions, and investigating its potential uses in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1092304-85-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,3,0 and 4 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1092304-85:
(9*1)+(8*0)+(7*9)+(6*2)+(5*3)+(4*0)+(3*4)+(2*8)+(1*5)=132
132 % 10 = 2
So 1092304-85-2 is a valid CAS Registry Number.
1092304-85-2Relevant academic research and scientific papers
From fragment screening to in vivo efficacy: Optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (bace1)
Cheng, Yuan,Judd, Ted C.,Bartberger, Michael D.,Brown, James,Chen, Kui,Fremeau Jr., Robert T.,Hickman, Dean,Hitchcock, Stephen A.,Jordan, Brad,Li, Vivian,Lopez, Patricia,Louie, Steven W.,Luo, Yi,Michelsen, Klaus,Nixey, Thomas,Powers, Timothy S.,Rattan, Claire,Sickmier, E. Allen,St. Jean Jr., David J.,Wahl, Robert C.,Wen, Paul H.,Wood, Stephen
, p. 5836 - 5857 (2011/10/09)
Using fragment-based screening of a focused fragment library, 2-aminoquinoline 1 was identified as an initial hit for BACE1. Further SAR development was supported by X-ray structures of BACE1 cocrystallized with various ligands and molecular modeling studies to expedite the discovery of potent compounds. These strategies enabled us to integrate the C-3 side chain on 2-aminoquinoline 1 extending deep into the P2′ binding pocket of BACE1 and enhancing the ligand's potency. We were able to improve the BACE1 potency to subnanomolar range, over 106-fold more potent than the initial hit (900 μM). Further elaboration of the physical properties of the lead compounds to those more consistent with good blood-brain barrier permeability led to inhibitors with greatly improved cellular activity and permeability. Compound 59 showed an IC50 value of 11 nM on BACE1 and cellular activity of 80 nM. This compound was advanced into rat pharmacokinetic and pharmacodynamic studies and demonstrated significant reduction of Aβ levels in cerebrospinal fluid (CSF).
